Meningioma Clinical Trial
Official title:
Treatment of Patients With Atypical Meningiomas Simpson Grade 4 and 5 With a Carbon Ion Boost in Combination With Postoperative Photon Radiotherapy: A Phase II Trial
Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection. With this approach, local control ranges between 50 and 70%, depending on resection status. A series or smaller studies has shown that postoperative radiotherapy in this patient population can increase progression-free survival, which translates into increased overall survival. However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed. First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising. Therefore, in the current Phase II-MARCIE-Study a carbon ion boost will be applied to the macroscopic tumor (gross tumor volume, GTV) in conjunction with photon radiotherapy to the clinical target volume (CTV) in patients with atypical meningiomas after incomplete resection or biopsy. Primary endpoint is progression-free survival rate, secondary endpoints are overall survival, safety and toxicity.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
Recruiting |
NCT03631953 -
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
|
Phase 1 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Completed |
NCT01811524 -
The Etiology and Progression of Brain Tumors
|
N/A | |
Completed |
NCT03648034 -
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
|
N/A | |
Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
Recruiting |
NCT06014905 -
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
|
Phase 1 | |
Not yet recruiting |
NCT04386642 -
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
|
Phase 4 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Completed |
NCT04305470 -
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
|
Phase 3 | |
Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02978677 -
Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas
|
N/A | |
Active, not recruiting |
NCT02933736 -
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
|
Early Phase 1 | |
Completed |
NCT02267928 -
Information Presentation Formats
|
N/A | |
Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
Active, not recruiting |
NCT03071874 -
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
|
Phase 2 | |
Recruiting |
NCT05416567 -
Embolization for Meningioma
|
N/A |